)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Sionna Therapeutics
Sionna Therapeutics (SION) investor relations material
Sionna Therapeutics Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary12 May, 2026
Leadership and expertise
Executive team and board have extensive experience in rare disease, biotech, and CF drug development.
Founders and key scientists have backgrounds at Genzyme, Sanofi, Vertex, and other leading firms.
Scientific foundation and innovation
Over 15 years of CFTR research, with origins in Genzyme and Sanofi, underpin the pipeline.
Focus on stabilizing NBD1, a critical domain affected in ~90% of CF patients with the F508del mutation.
NBD1 stabilization shown to restore CFTR half-life and function to wild-type levels in preclinical studies.
Pipeline and clinical progress
Lead NBD1 stabilizers SION-719 and SION-451 advanced through successful Phase 1 trials, showing favorable PK and safety.
SION-719 is being evaluated as an add-on to standard of care (SOC) in a Phase 2a POC trial; SION-451 is anchor for dual combinations.
Dual combinations with complementary correctors (SION-2222, SION-109) are in Phase 1 trials, with topline data expected summer 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sionna Therapeutics
- Q1 2026 net loss rose to $26.8M; cash reserves fund operations into 2028, topline data due summer 2026.SION
Q1 202612 May 2026 - Vote on four director elections and auditor ratification at the June 17, 2026, virtual meeting.SIONProxy filing27 Apr 2026
- 2026 meeting to elect directors, ratify auditor, and highlight governance and compensation practices.SIONProxy filing27 Apr 2026
- Advancing novel NBD1 stabilizers for CF, with pivotal data expected mid-2026 and strong cash runway.SIONLeerink Global Healthcare Conference 202610 Mar 2026
- NBD1 stabilizers aim to set a new efficacy bar in CF by targeting unmet needs beyond current therapies.SIONTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Advancing NBD1 stabilizers for CF with strong clinical progress and cash runway into 2028.SIONCorporate presentation2 Mar 2026
- Advanced pipeline and strong cash position support operations into 2028; key data due mid-2026.SIONQ4 20252 Mar 2026
- NBD1 stabilizer programs target major CF mutations, with pivotal data expected mid-2026.SIONGuggenheim Securities Emerging Outlook: Biotech Summit 202611 Feb 2026
- Advancing NBD1 stabilizers to transform CF care, with key data expected mid-2026.SION44th Annual J.P. Morgan Healthcare Conference13 Jan 2026
Next Sionna Therapeutics earnings date
Q2 202610 Aug, 2026
Sionna Therapeutics
Next Sionna Therapeutics earnings date
Q2 202610 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage